|Description||TAS-103, also known as BMS-247615, is a quinoline derivative that displays antitumor activity in murine and human tumor models. TAS-103 has been reported to be a potent topoisomerase II poison. TAS-103 showed the strongest antitumor activity among the conventional anticancer agents for colorectal cancer (p<0.05). The combination with CDDP augmented the antitumor activity of TAS-103 (p<0.05), indicating that CDDP is one of the most potent candidates to be used in combination with TAS-103|
|Related CAS||174634-08-3 (Free base)|
|Appearance||Red solid powder|
|Synonyms||6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride; TAS103; TAS-103; TAS 103; BMS247615; BMS 247615; BMS-247615|
|Current Developer||Taiho (Originator), Bristol-Myers Squibb (Licensee)|
Amsacrine is an antineoplastic agent which can intercalate into the DNA of tumor cells. It also expresses topoisomerase inhibitor activity, specifically inhibit...
Pirarubicin is an anthracycline antibiotic, and also a DNA/RNA synthesis inhibitor by intercalating into DNA and interacts with topoisomerase II, used as an ant...
UK-1, a benzoxazol derivative, has been found to a Streptomyces metabolite that could exhibit anticancer activity and topoisomerase II restraination activity.
Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
The deuterium labeled banoxantrone which was rationally designed to have anti-tumor activity following bioreduction by tissue cytochrome P450 to AQ4, an active ...
Topocecan is a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes top...
Grepafloxacin is a quinoline antibacterial agent used to treat various bacterial infections.
CP 117227, a dibenzocyclohepten derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed in studies of anticancer.